Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24098062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marko Kumric und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primarily a consequence of sedentary lifestyle, atherosclerosis has already reached pandemic proportions, and with every year the burden of it is only increasing. As low-density lipoprotein cholesterol (LDL-C) represents a crucial factor in atherosclerosis formation and progression, stringent lipid-lowering therapy could conceivably be the key to preventing the unfavorable outcomes that arise as a consequence of atherosclerosis. The use of statins in lipid-lowering is often burdened by adverse events or is insufficient to prevent cardiovascular events as a monotherapy. Therefore, in the present review, the authors aimed to discuss the underlying mechanisms of dyslipidemia and associated atherosclerotic cardiovascular disease (ASCVD) and preclinical and clinical trials of novel therapeutic approaches to its treatment, some of which are still in the early stages of development. Apart from novel therapies, a novel change in perspective is needed. Specifically, the critical objective in the future management of ASCVD is to embrace emerging evidence in the field of atherosclerosis, because clinicians are often burden by common practice and personal experience, both of which have so far been shown to be futile in the setting of atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
- Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital of Split, 21000 Split, Croatia.
- Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
ORCID-Profile: Marko Kumric, Josko Bozic, Marino Vilovic, Jaksa Zanchi, Josip A Borovac
Zitieren
APA
Kumric, M., Urlic, H., Bozic, J., Vilovic, M., Ticinovic Kurir, T., Glavas, D., Miric, D., Zanchi, J., Bradaric-Slujo, A., Lozo, M., & Borovac, J. A. (2023). Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098062
Vancouver
Kumric M, Urlic H, Bozic J, Vilovic M, Ticinovic Kurir T, Glavas D, et al. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098062
BibTeX
@article{Kumric2023,
author = {Kumric, Marko and Urlic, Hrvoje and Bozic, Josko and Vilovic, Marino and Ticinovic Kurir, Tina and Glavas, Duska and Miric, Dino and Zanchi, Jaksa and Bradaric-Slujo, Anteo and Lozo, Mislav and Borovac, Josip A},
title = {Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24098062}
}
EUVIMED